Article Text

PDF
MHRA Drug Safety Update: denosumab (Xgeva) and rebound hypercalcaemia

Abstract

Review of: Medical and Healthcare products Regulatory Agency. Denosumab for giant cell tumor of bone: risk of clinically significant hypercalcaemia following discontinuation. Drug Safety Update 2018;11(11);2.

Statistics from Altmetric.com

Footnotes

  • Provenance and peer review Internally peer reviewed.

  • Contributors DTB Team.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.